Anticoagulation Management in Deep Vein Thrombosis

Introduction to Warfarin Initiation

• The American College of Chest Physicians recommends initiating warfarin at 10 mg daily for the first 2 days, followed by dosing based on INR measurements, for patients with deep vein thrombosis (DVT) 1
• A 10 mg starting dose of warfarin leads to faster achievement of therapeutic INR (4.2 days vs 5.6 days) and a higher proportion of patients reaching therapeutic range by day 5 (86% vs 45%) 1
• The 10 mg starting dose has a similar safety profile compared to lower starting doses, according to the American College of Chest Physicians 1

Overlapping Anticoagulation Therapy

• When initiating warfarin for DVT treatment, it must be overlapped with a parenteral anticoagulant, such as heparin, LMWH, or fondaparinux, for a minimum of 5 days, as recommended by the American Heart Association 2
• The parenteral anticoagulant should be continued until the INR is ≥2.0 for at least 24 hours, according to the American Heart Association 2
• For cancer patients, LMWH monotherapy is preferred over transitioning to warfarin, as recommended by the European Society for Medical Oncology 3

Target INR and Duration of Therapy

• The standard target INR for DVT treatment is 2.0-3.0, with a strength of evidence rated as high, as recommended by the American Heart Association 2, 4
• The duration of therapy depends on risk factors and whether the DVT is provoked or unprovoked, according to the American Heart Association 2

Special Considerations

• Cancer patients require special consideration, and LMWH monotherapy is preferred over warfarin for cancer-associated DVT, as recommended by the European Society for Medical Oncology 3
• Outpatient vs inpatient protocols may differ, and the 10 mg loading dose is specifically recommended for outpatients healthy enough for outpatient management, according to the American College of Chest Physicians 1
• For patients transitioning from Lovenox to warfarin, the European Society of Cardiology recommends starting with 5 mg daily dosing rather than higher loading doses, with INR monitoring on day 4 and day 6, then twice weekly until stable 5
• The American College of Chest Physicians suggests that lower initial doses (2-4 mg) should be considered for elderly patients, debilitated patients, patients with hepatic insufficiency, and patients with potential for greater than expected INR response 1
• When transitioning from Lovenox to warfarin, the American Heart Association recommends continuing Lovenox at full therapeutic dose, starting warfarin at 5 mg daily concurrently, and continuing both medications for at least 5 days and until the INR is ≥2.0 for at least 2 consecutive days 5, 2, 4
• The National Comprehensive Cancer Network guidelines suggest that Lovenox should only be discontinued after achieving therapeutic INR (2.0-3.0) for two consecutive days 4
• The American College of Chest Physicians recommends an INR monitoring schedule of twice weekly until stable, then weekly initially, and gradually decreasing frequency to no less than once monthly 1, 4
• For patients with a history of resistance to oral anticoagulants, the American College of Cardiology suggests monitoring INR more frequently initially (twice weekly) until stability is demonstrated, considering a longer overlap period between Lovenox and warfarin, and being prepared to adjust dosing more aggressively if therapeutic INR is not achieved with standard dosing 5, 4
• The European Society of Cardiology recommends that most dose changes should alter the total weekly dose by 5-20%, with single INR values slightly out of range not requiring dose adjustment 5